Benitec Biopharma Files 8-K/A Amendment on Director/Officer Changes
Ticker: BNTC · Form: 8-K/A · Filed: Dec 31, 2024 · CIK: 1808898
Sentiment: neutral
Topics: corporate-governance, executive-compensation, amendment
TL;DR
Benitec Biopharma amended its 8-K filing on Dec 31, 2024, detailing director/officer changes and compensation from Dec 27.
AI Summary
Benitec Biopharma Inc. filed an amendment (8-K/A) on December 31, 2024, to a previous report concerning the departure of directors or certain officers, election of directors, and compensatory arrangements. The filing specifically addresses events that occurred on December 27, 2024, related to these corporate governance and executive compensation matters.
Why It Matters
This amendment provides updated information on the company's leadership and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially those concerning director and officer changes, can indicate internal shifts that may affect the company's stability and future performance.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- December 27, 2024 (date) — Date of earliest event reported
- December 31, 2024 (date) — Date of report
FAQ
What specific events are being amended in this 8-K/A filing?
This 8-K/A filing amends information related to the departure of directors or certain officers, the election of directors, and compensatory arrangements of certain officers.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is dated December 27, 2024.
When was this amendment filed with the SEC?
This amendment was filed on December 31, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 3940 Trust Way, Hayward, California, 94545.
What is Benitec Biopharma Inc.'s IRS Employer Identification Number?
Benitec Biopharma Inc.'s IRS Employer Identification Number is 84-4620206.
Filing Stats: 635 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-12-31 06:34:00
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
- $12.00 — ns were granted at an exercise price of $12.00 per share, which equals the closing pri
Filing Documents
- d905396d8ka.htm (8-K/A) — 24KB
- 0001193125-24-287065.txt ( ) — 144KB
- bntc-20241227.xsd (EX-101.SCH) — 2KB
- bntc-20241227_lab.xml (EX-101.LAB) — 17KB
- bntc-20241227_pre.xml (EX-101.PRE) — 11KB
- d905396d8ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: December 31, 2024 By: /s/ Dr. Jerel A. Banks Name: Dr. Jerel A. Banks Title: Chief Executive Officer